Notes · Biochemistry · 25 October 2026

Urea Cycle Disorders

Definition

• Urea cycle disorders (UCDs) are a group of inherited metabolic diseases caused by defects in the hepatic enzymes or transporters that convert toxic ammonia (NH₃) into urea for excretion.
• The urea cycle, also called the ornithine cycle, is the primary pathway for detoxifying ammonia generated from protein catabolism.

Epidemiology

• Combined incidence of all UCDs is approximately 1 in 35,000 live births worldwide.
• Individual disorders are rarer; for example, ornithine transcarbamylase (OTC) deficiency occurs in ≈1 in 80,000 males and 1 in 40,000 females (carrier frequency).
• Higher prevalence reported in populations with consanguineous marriages (e.g., Middle East, South Asia).

Aetiology (Genetic Basis)

• Autosomal recessive inheritance for all UCDs except OTC deficiency, which is X‑linked.
• Mutations affect one of six enzymes or two transporters:
  1. Carbamoyl‑phosphate synthetase I (CPS‑I) – mitochondrial enzyme that synthesizes carbamoyl phosphate from NH₃, CO₂, and 2 ATP.
  2. Ornithine transcarbamylase (OTC) – transfers carbamoyl group to ornithine, forming citrulline.
  3. Argininosuccinate synthetase (ASS) – combines citrulline with aspartate to produce argininosuccinate.
  4. Argininosuccinate lyase (ASL) – cleaves argininosuccinate into arginine and fumarate.
  5. Arginase I (ARG I) – hydrolyses arginine to urea and ornithine (final step).
  6. N‑acetylglutamate synthase (NAGS) – synthesises N‑acetylglutamate, an essential allosteric activator of CPS‑I.
  7. Mitochondrial ornithine transporter (ORNT1) – transports ornithine into mitochondria (citrullinemia type II).

Pathophysiology

• Normal cycle: NH₃ + CO₂ + 2 ATP → carbamoyl‑phosphate (CPS‑I); carbamoyl‑phosphate + ornithine → citrulline (OTC); citrulline + aspartate + ATP → argininosuccinate (ASS); argininosuccinate → arginine + fumarate (ASL); arginine + H₂O → urea + ornithine (ARG I).
• Defective enzyme → accumulation of upstream metabolites (e.g., citrulline, argininosuccinate) and ammonia.
• Hyperammonaemia: NH₃ crosses the blood‑brain barrier, is converted to glutamine in astrocytes, causing cerebral edema, altered neurotransmission, and neuronal injury.
• Secondary metabolic effects: Low arginine impairs nitric‑oxide synthesis; excess carbamoyl‑phosphate can be shunted into pyrimidine synthesis, causing orotic aciduria in OTC deficiency.

Clinical Features

• Neonatal onset (≈80 % of cases) – within first 24–48 h: poor feeding, lethargy, vomiting, seizures, rapid progression to coma and respiratory alkalosis.
• Late‑onset (adolescents/adults) – triggered by catabolic stress (infection, high‑protein diet, surgery): episodic encephalopathy, headaches, ataxia, psychiatric symptoms, recurrent vomiting.
• Gender differences: OTC deficiency severe in hemizygous males; heterozygous females may be asymptomatic or have milder intermittent symptoms due to X‑inactivation.
• Specific biochemical clues:
  • Elevated plasma ammonia (>100 µmol/L; normal <50 µmol/L).
  • Distinct amino‑acid profile depending on enzyme:
    • CPS‑I/NAGS deficiency – low citrulline, low arginine.
    • OTC deficiency – high glutamine, high orotic acid, low citrulline.
    • ASS deficiency (citrullinemia I) – markedly high citrulline.
    • ASL deficiency – high argininosuccinate, moderate citrulline.
    • ARG I deficiency – high arginine, low urea.

Investigations

• Plasma ammonia – rapid bedside assay; critical to obtain before treatment.
• Amino‑acid chromatography (plasma) – identifies pattern of accumulated substrates.
• Urine organic acids – orotic acid elevation suggests OTC deficiency; other organic acids help rule out organic acidemias.
• Genetic testing – targeted sequencing or whole‑exome sequencing confirms mutation; essential for family counseling.
• Liver function tests – usually normal unless secondary liver injury.
• Neuroimaging – MRI may show cerebral edema during acute hyperammonaemic crisis; chronic changes include white‑matter loss.

Management (Guidelines 2023)

1. Acute hyperammonaemia (life‑threatening):
   • Immediate ammonia‑lowering:
     • Intravenous sodium benzoate 5–10 g/m²/day (divided q6h) – conjugates glycine to form hippurate, excreted renally.
     • Sodium phenylacetate 5 g/m²/day (or sodium phenylbutyrate 9 g/m²/day) – forms phenylacetylglutamine, also renally cleared.
   • Dialysis:
     • Hemodialysis or continuous renal replacement therapy (CRRT) if ammonia >200 µmol/L or neurological deterioration despite medical therapy.
   • Caloric support:
     • High‑glucose (10 % dextrose) infusion at 8–10 mg/kg/min to suppress catabolism.
     • Avoid protein for first 24–48 h; re‑introduce low‑protein diet (0.5 g/kg/day) once ammonia falls <100 µmol/L.
2. Long‑term management:
   • Protein restriction: 0.6–1.0 g/kg/day (adjusted per disorder severity).
   • Supplemental essential amino acids (especially arginine for ASS, ASL, OTC deficiencies) – 100–200 mg/kg/day divided doses.
   • Nitrogen scavengers: chronic oral sodium benzoate or sodium phenylbutyrate (dose 8–12 g/m²/day).
   • Liver transplantation: definitive cure for most UCDs; indicated in recurrent crises despite optimal medical therapy, especially in infants with CPS‑I, OTC, or ASS deficiency.
   • Monitoring: quarterly plasma ammonia, annual amino‑acid profile, growth parameters, neurodevelopmental assessment.

Complications

• Neurological sequelae: intellectual disability, motor deficits, epilepsy due to repeated hyperammonaemic episodes.
• Cerebral edema – leading cause of mortality in neonatal crises.
• Growth failure – chronic protein restriction may impair weight gain if not balanced with adequate calories.
• Renal stones – from chronic use of sodium benzoate/phenylacetate (increased hippurate/phenylacetylglutamine excretion).
• Transplant‑related issues: immunosuppression, graft rejection, recurrence of hyperammonaemia if extra‑hepatic enzyme deficiency persists (rare).

High‑Yield Exam Points

• Key enzymes: CPS‑I, OTC, ASS, ASL, ARG I, NAGS; remember OTC is X‑linked.
• Biochemical hallmarks:
  • OTC deficiency – high ammonia + high orotic acid, low citrulline.
  • CPS‑I/NAGS deficiency – high ammonia, low citrulline, normal orotic acid.
  • ASS deficiency – citrullinemia (very high citrulline).
  • ASL deficiency – argininosuccinic aciduria.
  • ARG I deficiency – hyperargininemia, mild ammonia rise.
• Acute management hierarchy: stop protein → give glucose → nitrogen scavengers → dialysis if ammonia >200 µmol/L or coma.
• Why sodium benzoate works: conjugates with glycine → hippurate (excreted), removing one nitrogen per molecule.
• Why phenylbutyrate works: converted to phenylacetate → conjugates with glutamine → phenylacetylglutamine (excretes two nitrogens).
• Liver transplant: cures hepatic enzyme defect but does NOT correct extra‑hepatic N‑acetylglutamate synthase deficiency (rare).
• Maternal carriers: female heterozygotes for OTC may present during pregnancy or postpartum due to increased catabolism.

Practice questions

1. A 2‑day‑old male presents with vomiting, lethargy, and plasma ammonia of 350 µmol/L. Urine organic acids show marked orotic acid elevation, while plasma citrulline is low. Which enzyme is most likely deficient?
Answer: OTC – orotic acid accumulates because carbamoyl‑phosphate is shunted into pyrimidine synthesis.

2. Which of the following statements about sodium phenylbutyrate is correct?
A) It removes one nitrogen per molecule.
B) It is converted to phenylacetate, which conjugates with glutamine.
C) It requires renal excretion of hippurate.
D) It is contraindicated in neonates.
Answer: B — phenylbutyrate is metabolised to phenylacetate, which binds glutamine to eliminate two nitrogens.

3. A 7‑year‑old girl with episodic headaches and plasma ammonia of 120 µmol/L is found to have plasma citrulline of 800 µmol/L (normal <30). Which disorder does this pattern suggest?
Answer: Citrullinemia type I (argininosuccinate synthetase deficiency) – marked citrulline elevation.

AI-assisted study material for exam revision. Always confirm with standard textbooks and current guidelines; not medical advice.